Lipocine (LPCN)
(Real Time Quote from BATS)
$4.75 USD
-0.29 (-5.75%)
Updated Aug 8, 2024 01:50 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LPCN 4.75 -0.29(-5.75%)
Will LPCN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LPCN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LPCN
Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's Why
Here's Why Momentum in Lipocine (LPCN) Should Keep going
LPCN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LPCN
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
Lipocine GAAP EPS of -$0.56 beats by $0.22, revenue of $0.09M misses by $0.2M
Lipocine: Q2 Earnings Snapshot
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
Lipocine's LPCN 1154 meets bioequivalence with IV Brexanolone in pivotal study